618070-65-8

Basic information

• Product Name: ETHYL 5-AMINO-1-(2-FLUOROPHENYL)-1H-PYRAZOLE-4-CARBOXYLATE
• Synonyms: BUTTPARK 34\09-37;ETHYL 5-AMINO-1-(2-FLUOROPHENYL)-1H-PYRAZOLE-4-CARBOXYLATE;SALOR-INT L251526-1EA;OTAVA-BB 1218869;VITAS-BB TBB010286;ethyl 5-amino-1-(2-fluorophenyl)pyrazole-4-carboxylate;Ethyl 5-amino-1-(2-fluorophenyl)
• CAS NO: 618070-65-8
• Molecular Formula: C₁₂H₁₂FN₃O₂
• Molecular Weight: 249.24
• Mol File: 618070-65-8.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: ETHYL 5-AMINO-1-(2-FLUOROPHENYL)-1H-PYRAZOLE-4-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 5-AMINO-1-(2-FLUOROPHENYL)-1H-PYRAZOLE-4-CARBOXYLATE(618070-65-8)
• EPA Substance Registry System: ETHYL 5-AMINO-1-(2-FLUOROPHENYL)-1H-PYRAZOLE-4-CARBOXYLATE(618070-65-8)

Safety Data

• Hazardous Substances Data: 618070-65-8(Hazardous Substances Data)

Usage

General Description

Ethyl 5-amino-1-(2-fluorophenyl)-1H-pyrazole-4-carboxylate is a chemical compound with the molecular formula C12H12FN3O2. It is a pyrazole derivative that contains an ethyl ester group, an amino group, and a carboxylate group. The presence of the fluorophenyl group indicates that it contains a fluorine atom bonded to a phenyl group. ethyl 5-amino-1-(2-fluorophenyl)-1H-pyrazole-4-carboxylate may have potential applications in medicinal chemistry and pharmaceutical research, as it possesses structural features that are commonly found in bioactive molecules. However, as with any chemical compound, it should be handled and used with appropriate safety precautions and in accordance with established guidelines and regulations.

Upstream product

• 68350-76-5 2-cyano-3-methoxyacrylic acid ethyl ester 
• 2368-80-1 2-fluorophenylhydrazine 
• 94-05-3 ethyl (ethoxymethylene)cyanoacetate 
• 348-54-9 2-Fluoroaniline 

Downstream Products

• 618091-61-5 5-amino-1-(2-fluorophenyl)-1H-pyrazole-4-carboxylic acid 

Relevant articles and documents

Deciphering the robustness of pyrazolo-pyridine carboxylate core structure-based compounds for inhibiting α-synuclein in transgenic C. elegans model of Synucleinopathy

Parkinson's disease (PD), a calamitous neurodegenerative disorder with no cure till date, is closely allied with the misfolding and aggregation of α-Synuclein (α -Syn). Inhibition of α-Syn aggregation is one of the optimistic approaches for the treatment for PD. Here, we carried out hypothesis-driven studies towards synthesising a series of pyrazolo-pyridine carboxylate containing compounds (7a–7m) targeted at reducing deleterious α-Syn aggregation. The target compounds were synthesized through multi-step organic synthesis reactions. From docking studies, compounds 7b, 7g and 7i displayed better interaction with the key residues of α-Syn with values: ?6.8, ?8.9 and ?7.2 Kcal/mol, respectively. In vivo transgenic C. elegans model of Synucleinopathy was used to evaluate the ability of the designed and synthesized compounds to inhibit α-Syn aggregation. These lead compounds 7b, 7g and 7i displayed 1.7, 2.4 and 1.5-fold inhibition of α-Syn with respect to the control. Further, the strategy of employing pyrazolo-pyridine-based compounds worked with success and these scaffolds could be further modified and validated for betterment of endpoints associated with PD.